CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,024,322 | -11.2% | 37,221 | +9.4% | 0.00% | 0.0% |
| Q2 2023 | $1,153,891 | -28.9% | 34,008 | -24.6% | 0.00% | 0.0% |
| Q1 2023 | $1,623,706 | +0.3% | 45,128 | +24.2% | 0.00% | 0.0% |
| Q4 2022 | $1,618,916 | +71.9% | 36,323 | +8.4% | 0.00% | 0.0% |
| Q3 2022 | $942,000 | -79.5% | 33,512 | -80.3% | 0.00% | -66.7% |
| Q2 2022 | $4,589,000 | +80.0% | 170,214 | +127.4% | 0.00% | +200.0% |
| Q1 2022 | $2,550,000 | -32.6% | 74,857 | -23.5% | 0.00% | -50.0% |
| Q4 2021 | $3,782,000 | +54.7% | 97,896 | +116.3% | 0.00% | +100.0% |
| Q3 2021 | $2,444,000 | +111.1% | 45,259 | +30.7% | 0.00% | 0.0% |
| Q2 2021 | $1,158,000 | +2216.0% | 34,631 | +1338.2% | 0.00% | – |
| Q1 2021 | $50,000 | -96.5% | 2,408 | -97.1% | 0.00% | -100.0% |
| Q4 2020 | $1,441,000 | -75.4% | 82,232 | -79.1% | 0.00% | -75.0% |
| Q3 2020 | $5,847,000 | – | 394,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |